GSK (LON:GSK) Announces Earnings Results

GSK (LON:GSK) announced its quarterly earnings data on Wednesday. The company reported GBX 54.60 earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a return on equity of 24.64% and a net margin of 12.97%. The business had revenue of GBX 888.70 billion during the quarter.

GSK Stock Performance

LON GSK opened at GBX 1,856.50 on Friday. The company has a fifty day moving average of GBX 1,846.89 and a two-hundred day moving average of GBX 1,949.03. The company has a market capitalization of £74.39 billion, a PE ratio of 15.76, a P/E/G ratio of 1.24 and a beta of 0.29. GSK has a 1 year low of GBX 1,690 and a 1 year high of GBX 2,282. The company has a debt-to-equity ratio of 126.38, a current ratio of 0.86 and a quick ratio of 0.73.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK reported third-quarter revenue of approximately £8.9 billion and earnings of 54.60 pence per share, modestly exceeding expectations. Specialty medicines and newer products drove sales growth. GSK tops third-quarter estimates as new medicines drive growth, keeps outlook
• Positive Sentiment: The company maintained its 2026 guidance for 3% to 5% turnover growth and 7% to 9% growth in core operating profit and core EPS, indicating that management still expects its growth strategy to remain on track. GSK keeps guidance as specialty drugs power sales
• Neutral Sentiment: Deutsche Bank reaffirmed its “hold” rating and set a GBX 2,000 price target, suggesting some potential upside from recent levels but limited conviction in a stronger near-term re-rating. Deutsche Bank GSK rating
• Negative Sentiment: Vaccine sales fell 2%, including a 5% decline for Shingrix and a 24% drop for Arexvy. The weakness overshadowed the quarterly beat and raised concerns about demand for important vaccine products. GSK slides as weak vaccine sales overshadow quarterly beat
• Negative Sentiment: A £328 million restructuring charge connected with GSK’s Accelerate Growth program contributed to a 16% decline in reported operating profit and a 21% fall in total EPS. Investors may also be disappointed that management reaffirmed, rather than raised, its guidance. GSK Q3 2026 revenue and restructuring charges

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent research reports. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research note on Tuesday, October 20th. Royal Bank Of Canada initiated coverage on shares of GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 price objective for the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research note on Thursday. Finally, Berenberg Bank increased their target price on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a report on Tuesday, September 15th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of GBX 2,064.38.

Insider Transactions at GSK

In other news, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal bought 637 shares of GSK stock in a transaction dated Friday, September 18th. The stock was purchased at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Insiders have bought 2,151 shares of company stock worth $6,021,921 in the last quarter. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.